TB-500 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
More than 80% of newborns develop jaundice within several days of birth. Jaundice, or yellowing of the skin and eyes, occurs when bilirubin, a byproduct of the breakdown/recycling of red blood cells, builds up in the newborn's bloodstream faster than the liver can break it down and excrete it through the baby's urine and stool. By continuing to breastfeed frequently (start at 8-12 times per day), the infant's body can usually rid itself of the bilirubin excess by encouraging more urine and stool production. However, in some cases, the infant may need additional treatments, such as UV light therapy or additional feedings (see Supplementation) to keep the condition from progressing into more severe problems. There are two types of newborn jaundice related to breastfeeding. Breastfeeding jaundice is quite common and may occur in the first week of life in conjunction with ongoing weight loss. The cause is thought to be low caloric intake. Formula-fed infants tend to lose less weight after birth compared to breastfed infants, supporting the hypothesis that breastfeeding jaundice is related to caloric intake rather than volume intake. Individual risk factors, such as breastfeeding, are not predictive of developing severe jaundice: Breastfeeding is a risk factor for severely high levels of bilirubin, but the risk factor is very common, and the risk of severely high bilirubin remains small. Breast milk jaundice is jaundice that persists despite appropriate weight gain.
== History == Vitacost began operations in 1994 as a catalog retailer of third-party vitamins and supplements under the name Nature's Wealth Company by its founder Wayne Gorsek. In 1999, the company launched Vitacost.com and introduced proprietary vitamins and supplements, which has since expanded to include food, beauty products and sports nutrition. The company completed construction of a manufacturing facility located in Lexington, North Carolina, in 2008. Effective September 1, 2012, Vitacost agreed to lease its manufacturing facilities to a third-party provider. On September 23, 2009, Vitacost went public. Vitacost shares traded on the NASDAQ were suspended on December 7, 2010, for financials not adding up. By the time the stock was reinstated by NASDAQ, the stock had lost most of its value with investors losing almost all of their investment. ("Gebben"). During 2010, the company expanded and upgraded its West Coast distribution facility located in Las Vegas, Nevada. The Company began a similar project for its east coast distribution center, located in Lexington, North Carolina in the spring of 2010, with the building construction completed in the first quarter of 2011. Gorsek was found guilty of securities fraud on January 28, 2003. The SEC Commission announced on this day that the Honorable Jeanne E. Scott, U.S. District Judge for the Central District of Illinois, has found two former brokers and stock promoters, Wayne F. Gorsek ("Gorsek") and Lyndell F.
Robert Blake, Assistant Secretary of State for South and Central Asian Affairs, dismissed any concerns over a rift with India regarding American Af-Pak policy. Calling India and the United States "natural allies", Blake said that the United States cannot afford to meet the strategic priorities in Pakistan and Afghanistan at "the expense of India". India criticized the Obama administration's decision to limit H-1B (temporary) visas, and India's then External Affairs Minister Pranab Mukherjee (later, the president of India until 2017) said that India would oppose US "protectionism" at various international forums. India's Commerce Minister Kamal Nath said that India may move against Obama's outsourcing policies at the World Trade Organization. In May 2009, Obama reiterated his anti-outsourcing views and criticized the current US tax policy "that says you should pay lower taxes if you create a job in Bangalore, India, than if you create one in Buffalo, New York." However, during the US India Business Council meeting in June 2009, U.S. Secretary of State Hillary Clinton advocated for stronger economic ties between India and the United States. She also rebuked protectionist policies, saying that the U.S will not use the 2008 financial crisis as an excuse to implement protectionism. In June 2010, the United States and India formally re-engaged the US-India Strategic Dialogue initiated under President Bush when a large delegation of high-ranking Indian officials, led by External Affairs Minister S. M. Krishna, visited Washington, D.C.
Sources: en.wikipedia.org
=== Barrier function === The fetal membranes separate maternal tissue from fetal tissue at a basic mechanical level. The fetal membrane is composed of a thick cellular chorion covering a thin amnion composed of dense collagen fibrils. The amnion is in contact with the amniotic fluid and ensures structural integrity of the sac due to its mechanical strength. The underlying chorion is fused to the decidua at the maternal-fetal interface. This interaction is vital in controlling the local immune systems which in turn is vital for maintaining a semi-allogeneic fetus. At the end of gestation, a 'weak zone' develops in the fetal membrane overlying the cervix due to collage remodelling. This eventually leads to rupture of the fetal membrane and the onset of labour.
In the 1990s, collaboration with physicist Ken Standing's group at the University of Manitoba led to the introduction of the QSTAR quadrupole/time-of-flight (QTOF) instrument in 1999, which evolved into the present day line of ZENO TOF 7600 series and benchtop X500-Series products. In 2010, SCIEX acquired the liquid chromatography business of Eksigent Corporation and now offers a range of liquid chromatographs that couple to their mass spectrometers. The SelectION differential ion mobility spectrometer was introduced as an alternative method of separation in front of the mass spectrometer.
The Maronite Catholic and the Druze founded modern Lebanon in the early eighteenth century, through the ruling and social system known as the "Maronite-Druze dualism" in Mount Lebanon Mutasarrifate. Contact between Christians (members of the Maronite, Eastern Orthodox, Melkite, and other churches) and the Unitarian Druze led to the presence of mixed villages and towns in Mount Lebanon, Chouf, Wadi al-Taym, Jabal al-Druze, the Galilee region, Mount Carmel, and Golan Heights. They both speak the Arabic language and follow a social patterns similar to those of other peoples in the Levant (Eastern Mediterranean). Scholars classify Antiochian Greek Christians, Druze, and Maronites as ethnoreligious groups. The relationship between the Druze and Christians in Syria, Lebanon and Israel has been characterized by harmony and peaceful coexistence. Historically, they lived in the Chuf Mountains in complete harmony. On a social level, Druze and Christians have often interacted in daily life, sharing neighborhoods, schools, and workplaces. Druze and Christians in these regions celebrate each other's births, weddings, funerals, and celebrations such as Christmas, Maundy Thursday (in Lebanon), Easter and the Christian festival of Saint Elias (in Mount Carmel). Before 2011, more than 55,000 Christians lived in As-Suwayda Governorate, the only governorate in Syria with a Druze majority. In 2010, more than 52,000 registered Christian voters, primarily Maronites and Greek Orthodox, lived in the Aley District, where Druze constitute the majority.
Cell signaling is the process by which a cell interacts with itself, other cells, and the environment. Typically, the signaling process involves three components: the first messenger (the ligand), the receptor, and the signal itself. Most cell signaling is chemical in nature, and can occur with neighboring cells or more distant targets. Signal receptors are complex proteins or tightly bound multimer of proteins, located in the plasma membrane or within the interior. Each cell is programmed to respond to specific extracellular signal molecules, and this process is the basis of development, tissue repair, immunity, and homeostasis. Individual cells are able to manage receptor sensitivity including turning them off, and receptors can become less sensitive when they are occupied for long durations. Errors in signaling interactions may cause diseases such as cancer, autoimmunity, and diabetes.
Sources: en.wikipedia.org
One of the groups, the Camp of National Unity, combined many nationalists with Sanation supporters and was connected to the new strongman, Marshal Edward Rydz-Śmigły, whose faction of the Sanation ruling movement was increasingly nationalistic. In the late 1930s, the exile bloc Front Morges united several major Polish anti-Sanation figures, including Ignacy Paderewski, Władysław Sikorski, Wincenty Witos, Wojciech Korfanty and Józef Haller. It gained little influence inside Poland, but its spirit soon reappeared during World War II, within the Polish government-in-exile.
is the fact that unipolarity has not provoked a global alarm to restore a balance of power." The same anomaly stressed seventeen other experts on alliances, Stephen Walt, Randall Schweller, Xiaoyu Pu, John Ikenberry, Robert Pape, T. V. Paul, Jack S. Levy, William R. Thompson, John Lewis Gaddis, David A. Lake, Campbell Craig, Fareed Zakaria, John M. Owen, Michael Mastanduno, Thomas S. Mowle, David H. Sacko and Terry Narramore:
=== Preclinical === ASD-002 - a child-specific (non-acidic, sustained-release) anti-hyper excitatory ester prodrug of the potassium channel modulator NSAID mefenamic acid (MFA, approved as Ponstel) to prevent toddlers from becoming non-verbal (developmental language disorder, DLD) Bryostatin-1 (MW-904) – protein kinase C stimulant CJRB-303 (CJRB-901, MRx-0006) – bacteria replacement Debamestrocel (growth factor-producing stem cell therapy) – dopaminergic cell replacement therapy FIN-211 – bacteria replacement and gastrointestinal microbiome modulator Levophacetoperane (NLS-3; (R,R)-phacetoperone; methylphenidate reverse ester) – norepinephrine and dopamine reuptake inhibitor and psychostimulant LIT-001 – small-molecule oxytocin receptor agonist MBDB – serotonin and norepinephrine releasing agent and weak serotonin 5-HT1 and 5-HT2 receptor ligand (entactogen) Psilocin (PLZ-1015) – non-selective serotonin receptor agonist and psychedelic hallucinogen QBM-001 – undefined mechanism of action (allosteric channel modulator; putative neuroprotective and anti-inflammatory agent)
There is no level of BNP that perfectly separates patients with and without heart failure. In screening for congenital heart disease in pediatric patients, an NT-proBNP cut-off value of 91 pg/mL could differentiate an acyanotic heart disease (ACNHD) patient from a healthy patient with a sensitivity of 84% and specificity of 42%. On the other hand, an NT-proBNP cut-off value of 318 pg/mL is more appropriate in differing patients with congenital nonspherocytic hemolytic disease (CNHD) from healthy patients, with 94% sensitivity and 97% specificity. An NT-proBNP value of 408 pg/mL has been estimated to be 83% sensitive and 57% specific in differentiating patients with ACNHD from patients with CNHD. In patients with non-severe asymptomatic aortic valve stenosis, increased age- and sex adjusted NT-proBNP levels alone and combined with a 50% or greater increase from baseline had been found associated with increased event rates of aortic valve stenosis related events (cardiovascular death, hospitalization with heart failure due to progression of aortic valve stenosis, or aortic valve replacement surgery). In severe aortic valve stenosis, NT-proBNP provide important prognostic information beyond clinical and echocardiographic evaluation. Recent studies have found associations between long-term excessive variation in blood pressure and elevations in NT-proBNP levels.
== Plot == In 1982, French President François Mitterrand launches an anonymous international competition to design a monumental building on the historic axis linking the Louvre and the Arc de Triomphe. To general surprise, the winning entry comes not from one of the world's major architectural firms but from Johan Otto von Spreckelsen, a 53-year-old architecture teacher from Copenhagen who is unknown in France and has previously built only a handful of structures, including his own house and three small chapels. Overnight, von Spreckelsen is put in charge of the largest building project of the era, the Grande Arche de la Défense, which he affectionately calls his "cube". Determined to see the structure built exactly as he first envisioned it, he clashes repeatedly with the realities of French bureaucracy, represented chiefly by project administrator Jean-Louis Subileau, and with the pragmatic French architect Paul Andreu, who is brought in to oversee the building's technical execution. His uncompromising attachment to his original design, including a marble cladding that proves both structurally troublesome and hugely expensive, increasingly isolates him from the project's engineers and financiers. When the 1986 legislative elections bring a new, right-wing government to power in cohabitation with Mitterrand, the political backing that had protected von Spreckelsen evaporates. The film ends on a bleak note: worn down by the years-long conflict, von Spreckelsen dies before the Grande Arche is completed, which is inaugurated two years later.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.